Transcode Therapeutics stock hits 52-week low at $1.7

Transcode Therapeutics, Inc. (RNAZ) stock has reached a 52-week low, trading at $1.7, marking a significant downturn for the biotech company. With a market capitalization of just $1.25 million, InvestingPro analysis suggests the stock is currently undervalued, though it maintains a weak financial health score. Over the past year, the stock has experienced a precipitous decline, with a 1-year change showing a staggering 92.4% drop in value. Despite the sharp decline, the company maintains a healthy current ratio of 1.58 and holds more cash than debt on its balance sheet. This downturn reflects investor concerns and broader market trends affecting the biotech sector, as Transcode Therapeutics grapples with the challenges of advancing its RNA-targeted cancer therapies amidst a competitive and rapidly evolving industry landscape. Discover 14 additional key insights about RNAZ with an InvestingPro subscription.

In other recent news, TransCode Therapeutics has reported progress in its Phase 1 clinical trial for TTX-MC138, a treatment targeting microRNA-10b in metastatic cancers. The Safety Review Committee has approved the advancement to Cohort 3 after finding no significant safety concerns or dose-limiting toxicities in the second cohort. This approval allows the trial to continue with a higher dosage for the third cohort. Preliminary data indicate that TTX-MC138’s pharmacokinetic and pharmacodynamic profiles are consistent with earlier preclinical and Phase 0 results, showing a 66% inhibition of miR-10b at 24 hours post-infusion in patients with high baseline expression.

Additionally, H.C. Wainwright has significantly raised its price target for TransCode Therapeutics from $3.00 to $20.00, maintaining a Buy rating. This adjustment follows the company’s announcement of the SRC’s approval to proceed with Cohort 3. The firm notes that the study is still in early stages, with initial cohorts potentially below therapeutic dose levels. TransCode continues to enroll patients for the trial, aiming to establish the safety and tolerability of TTX-MC138 across various metastatic solid tumors. These developments highlight TransCode’s ongoing efforts to address metastatic disease through RNA therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.